** = Publikationen gelistet in SCI/SSCI/Pubmed
** Smolle, MA; Helmberg, W; Matzhold, EM; Barth, DA; Sareban, N; Szkandera, J; Liegl-Atzwanger, B; Leithner, A; Pichler, M
Impact of allogeneic red blood cell transfusion on prognosis in soft tissue sarcoma patients. A single-centre study.
Cancer Med. 2023; 12(2):1237-1246
Doi: 10.1002/cam4.4989
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Barth, D; Stradner, M; Hutterer, H; Spiegelberg, J; Bauernhofer, T; Absenger, G; Jost, P; Pichler, M
Blood-based B-cell subtypes as predictors of treatment response during treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology 2022. 2022; -OeGHO Frühjahrstagung 2022; APR 8-10, 2022; Graz, AUSTRIA.
[Poster]
Barth, DA; Pichler, M;
Pathophysiology roles and translational opportunities of miRNAs in Renal cancer.
In: Negrini, M; Calin, GA; Croce, C; editors(s). MicroRNA in Human Malignancies. Elsevier; 2022(ISBN: 9780128222874)
** Barth, DA; Stanzer, S; Spiegelberg, J; Bauernhofer, T; Absenger, G; Posch, F; Lipp, R; Halm, M; Szkandera, J; Balic, M; Gerger, A; Smolle, MA; Hutterer, GC; Klec, C; Jost, PJ; Kargl, J; Stradner, M; Pichler, M
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Cancer Med. 2022; 11(16):3074-3083
Doi: 10.1002/cam4.4675
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Barth, DA; Stanzer, S; Spiegelberg, JA; Bauernhofer, T; Absenger, G; Szkandera, J; Gerger, A; Smolle, MA; Hutterer, GC; Ahyai, SA; Madl, T; Posch, F; Riedl, JM; Klec, C; Jost, PJ; Kargl, J; Stradner, MH; Pichler, M
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Front Immunol. 2022; 13: 840207
Doi: 10.3389/fimmu.2022.840207
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Fluhrer, H; Hutterer, GC; Golbeck, S; Stidl, M; Niedrist, T; Pichler, R; Mischinger, J; Seles, M; Mannweiler, S; Spiegelberg, J; Bauernhofer, T; Jost, PJ; Ahyai, S; Zigeuner, R; Pichler, M; Barth, DA
Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
Ther Adv Med Oncol. 2022; 14: 17588359221134065
Doi: 10.1177/17588359221134065
[OPEN ACCESS]
PubMed
FullText
FullText_MUG
** Juracek, J; Madrzyk, M; Stanik, M; Ruckova, M; Trachtova, K; Malcikova, H; Lzicarova, E; Barth, DA; Pichler, M; Slaby, O
A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer
PROSTATE. 2022;
Doi: 10.1002/pros.24466
Web of Science
PubMed
FullText
FullText_MUG
** Maisel, F; Smolle, MA; Mollnar, S; Riedl, JM; Barth, DA; Seles, M; Terbuch, A; Rossmann, CH; Eisner, F; Mannweiler, S; Hutterer, G; Zigeuner, R; Pummer, K; Smolle-Jüttner, FM; Lindenmann, J; Stotz, M; Gerger, A; Jost, PJ; Bauernhofer, T; Pichler, M; Posch, F
Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.
Clin Genitourin Cancer. 2022; 20(4):344-353
Doi: 10.1016/j.clgc.2022.03.010
Web of Science
PubMed
FullText
FullText_MUG
** Moik, F; Riedl, J; Barth, D; Chan, WSE; Wiedemann, S; Holler, C; Fuereder, T; Jost, P; Pabinger, I; Preusser, M; Ay, C
Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors
BLOOD. 2022; 140: 1250-1251.
Doi: 10.1182/blood-2022-160087
[Oral Communication]
Web of Science
FullText
FullText_MUG
** Prinz, F; Jonas, K; Balihodzic, A; Klec, C; Reicher, A; Barth, DA; Riedl, J; Gerger, A; Kiesslich, T; Mayr, C; Rinner, B; Kargl, J; Pichler, M
MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response.
RNA Biol. 2022; 19(1):1305-1315
Doi: 10.1080/15476286.2022.2152978
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A
Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien.
[Poster]
Web of Science
** Riedl, JM; Schwarzenbacher, E; Moik, F; Horvath, L; Gantschnigg, A; Renneberg, F; Posch, F; Barth, DA; Stotz, M; Pichler, M; Hatzl, S; Fandler-Höfler, S; Gressenberger, P; Gary, T; Jost, PJ; Greil, R; Ay, C; Djanani, A; Gerger, A; Schlick, K
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Thromb Haemost. 2022; 122(4):633-645
Doi: 10.1055/a-1548-4847
Web of Science
PubMed
FullText
FullText_MUG
Smolle, MA; Helmberg, W; Barth, DA; Sareban, N; Szkandera, J; Liegl-Atzwanger, B; Leithner, A; Pichler, M
Prognostic Effect Of Allogeneic Red Blood Cell Transfusions In Soft Tissue Sarcoma Patients. A Retrospective Study.
Advanced Scientific Programme EFORT Congress. 2022; -EFORT Annual Congress; JUN 22-24, 2022; Lisbon, PORTUGAL.
[Oral Communication]
Smolle, MA; Helmberg, W; Barth, DA; Sareban, N; Szkandera, J; Liegl-Atzwanger, B; Leithner, A; Pichler, M
Einfluss der perioperativen Erythrozytenkonzentrat-Gabe auf die Prognose von Weichteilsarkom-patient*Innen. Eine retrospektive Studie.
Abstractband DKOU 2022. 2022; -Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU); OCT 25-28, 2022; Berlin, GERMANY.
[Oral Communication]
** Balihodzic, A; Barth, DA; Prinz, F; Pichler, M
Involvement of Long Non-Coding RNAs in Glucose Metabolism in Cancer.
Cancers (Basel). 2021; 13(5): 977
Doi: 10.3390/cancers13050977
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Barth, DA; Sareban, N; Lindner, AK; Daller, LAJ; Matzhold, EM; Hutterer, G; Smolle, M; Mischinger, J; Riedl, JM; Seles, M; Mannweiler, S; Bauernhofer, T; Pummer, K; Pichler, R; Zigeuner, R; Schlenke, P; Pichler, M
Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up.
Urol Oncol. 2021; 39(10):736.e9-736.e16
Doi: 10.1016/j.urolonc.2021.06.005
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Müller, M; Posch, F; Kiem, D; Barth, D; Horvath, L; Stotz, M; Schaberl-Moser, R; Pichler, M; Greil, R; Jost, PJ; Seeber, A; Amann, A; Schlick, K; Gerger, A; Riedl, JM
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
Ther Adv Med Oncol. 2021; 13: 17588359211039930
Doi: 10.1177/17588359211039930
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Posch, F; Prinz, F; Balihodzic, A; Mayr, C; Kiesslich, T; Klec, C; Jonas, K; Barth, DA; Riedl, JM; Gerger, A; Pichler, M
MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms.
Cancers (Basel). 2021; 13(16):
Doi: 10.3390/cancers13163996
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, DA; Rossmann, CH; Stotz, M; Schaberl-Moser, R; Pichler, M; Stöger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Eur J Cancer. 2021; 151: 3-13.
Doi: 10.1016/j.ejca.2021.03.040
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Scheipner, L; Smolle, MA; Barth, D; Posch, F; Stotz, M; Pichler, M; StÖger, H; Gerger, A; Riedl, JM
The AST/ALT Ratio Is an Independent Prognostic Marker for Disease-free Survival in Stage II and III Colorectal Carcinoma.
Anticancer Res. 2021; 41(1):429-436
Doi: 10.21873/anticanres.14792
Web of Science
PubMed
FullText
FullText_MUG
** Taheri, M; Barth, DA; Kargl, J; Rezaei, O; Ghafouri-Fard, S; Pichler, M
Emerging Role of Non-Coding RNAs in Regulation of T-Lymphocyte Function.
Front Immunol. 2021; 12: 756042
Doi: 10.3389/fimmu.2021.756042
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Barth, DA; Brenner, C; Riedl, JM; Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; Stöger, H; Stotz, M; Gerger, A; Pichler, M
External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients.
Cancer Med. 2020; 9(15):5473-5479
Doi: 10.1002/cam4.3233
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Barth, DA; Brenner, C; Riedl, JM;Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; Stöger, H; Stotz, M;Gerger, A; Pichler, M
External validation of the prognostic relevance of the Advanced Lung Cancer Infammation Index (ALI) in pancreatic cancer patients
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology 2020. 2020; 13 (Suppl 2): 23-65.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 19-21, 2020; Vienna, AUSTRIA.
[Poster]
** Barth, DA; Drula, R; Ott, L; Fabris, L; Slaby, O; Calin, GA; Pichler, M
Circulating Non-coding RNAs in Renal Cell Carcinoma-Pathogenesis and Potential Implications as Clinical Biomarkers.
Front Cell Dev Biol. 2020; 8:828
Doi: 10.3389/fcell.2020.00828
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Barth, DA; Juracek, J; Slaby, O; Pichler, M; Calin, GA
lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System.
Cancers (Basel). 2020; 12(8):
Doi: 10.3390/cancers12082148
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Barth, DA; Prinz, F; Teppan, J; Jonas, K; Klec, C; Pichler, M
Long-Noncoding RNA (lncRNA) in the Regulation of Hypoxia-Inducible Factor (HIF) in Cancer.
Noncoding RNA. 2020; 6(3):
Doi: 10.3390/ncrna6030027
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Henzinger, H; Barth, DA; Klec, C; Pichler, M
Non-Coding RNAs and SARS-Related Coronaviruses.
Viruses. 2020; 12(12):
Doi: 10.3390/v12121374
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Klocker, EV; Barth, DA; Riedl, JM; Prinz, F; Szkandera, J; Schlick, K; Kornprat, P; Lackner, K; Lindenmann, J; Stöger, H; Stotz, M; Gerger, A; Pichler, M
Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients.
Cancers (Basel). 2020; 12(5):
Doi: 10.3390/cancers12051154
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Lembeck, AL; Puchas, P; Hutterer, G; Barth, DA; Terbuch, A; Bauernhofer, T; Pichler, M
MicroRNAs as Appropriate Discriminators in Non-Specific Alpha-Fetoprotein (AFP) Elevation in Testicular Germ Cell Tumor Patients.
Noncoding RNA. 2020; 6(1):
Doi: 10.3390/ncrna6010002
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Posch, F; Barth, D; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Riedl, JM
C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study.
ANN ONCOL. 2020; 31: S286-S286.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.234
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
** Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis.
ONCOL RES TREAT. 2020; 43(SUPPL 4):215-215.
[Poster]
Web of Science
** Riedl, JM; Barth, DA; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoeger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Posch, F
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Cancers (Basel). 2020; 12(8):
Doi: 10.3390/cancers12082319
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis.
WIEN KLIN WOCHENSCHR. Abstracts 51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. 2020; 132(SUPPL 2):78-79.-51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24-26, 2020; Salzburg, AUSTRIA.
[Poster]
Web of Science
** Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
ANN ONCOL. 2020; 31: S942-S942.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2013
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
** Schwarzenbacher, E; Moik, F; Horvath, L; Renneberg, F; Posch, F; Barth, D; Gantschnigg, A; Schaberl-Moser, R; Pichler, M; Stotz, M; Stoger, H; Ay, C; Greil, R; Gerger, A; Djanani, A; Schlick, K; Riedl, J
Incidence, prediction and outcome of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of Gemcitabine/nab-Paclitxel or FOLFIRINOX.
ONCOL RES TREAT. 2020; 43(SUPPL 4):214-214.
[Poster]
Web of Science
** Schwarzenbacher, E; Moik, F; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Ay, C; Stoger, H; Greil, R; Djanani, A; Gerger, A; Schlick, K; Riedl, JM
Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX.
ANN ONCOL. 2020; 31: S949-S950.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2035
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
** Seles, M; Hutterer, GC; Foßelteder, J; Svoboda, M; Resel, M; Barth, DA; Pichler, R; Bauernhofer, T; Zigeuner, RE; Pummer, K; Slaby, O; Klec, C; Pichler, M
Long Non-Coding RNA PANTR1 is Associated with Poor Prognosis and Influences Angiogenesis and Apoptosis in Clear-Cell Renal Cell Cancer.
Cancers (Basel). 2020; 12(5): 1200
Doi: 10.3390/cancers12051200
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Stotz, M; Barth, DA; Riedl, JM; Asamer, E; Klocker, EV; Kornprat, P; Hutterer, GC; Prinz, F; Lackner, K; Stöger, H; Gerger, A; Pichler, M
The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer.
Cancers (Basel). 2020; 12(7):
Doi: 10.3390/cancers12071798
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Teppan, J; Barth, DA; Prinz, F; Jonas, K; Pichler, M; Klec, C
Involvement of Long Non-Coding RNAs (lncRNAs) in Tumor Angiogenesis.
Noncoding RNA. 2020; 6(4):
Doi: 10.3390/ncrna6040042
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Barth, D; Riedl, JM; Posch, F; Smolle, MA; Kasparek, AK; Niedrist, T; Szkandera, J; Stöger, H; Pichler, M; Gerger, A; Stotz, M
Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Proceedings of the Annual Meeting of the Austrian Society
of Haematology and Medical Oncology. 2019; -OeGHO Frühjahrstagung 2019; APR 11-13; Linz, AUSTRIA.
[Poster]
** Barth, DA; Riedl, JM; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A
External validation and longitudinal extension of the LIPI (lung immune prognostic index) for immunotherapy outcomes in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 108-108.
[Poster]
Web of Science
** Barth, DA; Riedl, JM; Posch, F; Smolle, MA; Kasparek, AK; Niedrist, T; Szkandera, J; Stöger, H; Pichler, M; Stotz, M; Gerger, A
Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Clin Transl Oncol. 2019; 21(8):1034-1043
Doi: 10.1007/s12094-019-02037-7
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Barth, DA; Slaby, O; Klec, C; Juracek, J; Drula, R; Calin, GA; Pichler, M
Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma.
Cancers (Basel). 2019; 11(10):
Doi: 10.3390/cancers11101580
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Barth, D; Posch, F; Foris, V; Absenger, G; Mollnar, S; Pichler, M; Stotz, M; Stoger, H; Olschewski, H; Gerger, A
Longitudinal C-reactive protein (CRP) trajectories predict immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 115-115.
[Poster]
Web of Science
** Riedl, JM; Barth, DA; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A
External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer
ANN ONCOL. 2019; 30: -44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN.
[Poster]
Web of Science